A Phase 3 interventional study of Chloroprocaine 3% and Tetracaine 0.5% in Cataract, sponsored by Sintetica SA. Completed at 27 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-18.
Sponsored by Sintetica SA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Cataract with a site in Italy — none open to participants now, 1 under way, none of them phase 3. Cataract · Italy.
Among the 28 studies in Cataract with a site in Italy, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 17th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →None of the 28 studies in Cataract with a site in Italy is open now. The open studies under Cataract, anywhere →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 338 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 121 across the 17 interventional studies, 100 across the 11 observational. Of the 25 that completed or were terminated, 7 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Sintetica SA has 1 study filed under Cataract — fewer than ten, so there is no comparison to draw.
1 of the studies in Cataract with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06093880SIFI SpAObservational, Prospective Clinical Investigation on Mini 4 Ready Intraocular Lens | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Cataract with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized clinical trial, multicenter, two-armed, to investigate and compare the clinical efficacy of chloroprocaine 3% gel and tetracaine 0.5% eye drop as topical anestheticsin phacoemulsification. This prospective, observer masked, randomised, controlled, equivalence phase 3 study will be conducted in approximately 4 European Countries. Sintetica intends to perform a phase 3 study on patients undergoing cataract surgery to assess the safety and efficacy of topical anaesthesia using chloroprocaine gel.
Prospective,randomized, multi-center, active-controlled, masked-observer, parallel-group, competitive equivalence study. The study has been designed to assess the equivalence of chloroprocaine 3% gel (Test) with respect to tetracaine 0.5% solution (Reference) in surface anesthesia. Patients in both groups will receive three drops of study products before surgery. The study will include a Selection visit (Day -90/Day -1), an Inclusion visit (Day 1/surgery day), a Follow-up visit (Day 2, phone visit), a Final visit (Day 8), and a Follow-up phone call - Optional (Day 28, phone visit).
Selection visit (Visit 1, Day -90/Day -1):
Patients scheduled to undergo cataract surgery in a single eye will be informed about the aims, procedures and possible risks of the study and will be asked to sign the informed consent form for the inclusion in the trial.
Inclusion visit/Surgery (Visit 2, Day 1):
Before the anesthesia, patients will be questioned about previous and concomitant ocular and non-ocular treatments. Inclusion /exclusion criteria and patient status will be verified. Patients will be randomized to either chloroprocaine 3% gel (Test) or tetracaine 0.5% eye drop (Reference) treatment group.
Follow-up visit/phone visit (Visit 3, Day 2):
Concomitant ocular and non-ocular treatments, AEs, and patient global satisfaction will be assessed.
Final visit (Visit 4, Day 8 ± 1 day):
Concomitant ocular and non-ocular treatments, ocular symptoms, best far corrected visual acuity in both eyes, endothelial cell count, corneal thickness, blood pressure and heart rate, and AEs will be assessed. Slit lamp examination and fluorescein test, IOP in both eyes, and fundoscopy will be performed.
Optional visit/phone visit (Visit 5, Day 28 ± 3 days):
Concomitant ocular and non-ocular treatments and AEs resolution will be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.
Drug: Chloroprocaine 3%
All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.
Drug: Tetracaine 0.5%
Administration: three IMP drops instillation as follow: * 1st Drop instillation, then wait for 5 minutes * Eye Disinfection, then wait for 2 minutes * 2nd Drop instillation, then wait for 1 minute * 3rdDrop instillation, then wait for 1 minute * Start of Surgery.
Also known as: Arm 1
Administration: three IMP drops instillation as follow: * 1st Drop instillation, then wait for 5 minutes * Eye Disinfection, then wait for 2 minutes * 2nd Drop instillation, then wait for 1 minute * 3rdDrop instillation, then wait for 1 minute * Start of Surgery.
Also known as: Arm 2
Number of Participants in Each Treatment Group With a Successful Surface Anesthesia
Τhe primary endpoint is the number of partecipants in each treatment group with a successful surface anesthesia, without any supplementation at the time point T4 (1 minute after the 3rd drop installation)
Time frame: Before Intra Ocular Lens (IOL) implantation surgery.
Changes in Ocular Symptoms
Changes in ocular symptoms (pain, irritation/burning/stinging, foreign body sensation) will be graded by the patients according to the following scale (0 is the minimum value and 3 is tha maximum value) (0 = absent, 1 = mild, 2 = moderate, 3 = severe) during the study on Visit 1-selection and on visit 4-final
Time frame: Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day), up to approximately 102 days
Objective Ocular Signs
- Objective ocular signs assessed by slit lamp examination, flare, and other objective ocular signs will be graded according to the following scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The minimum value is 0 and maximum value is 3
Time frame: Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day), up to approximately 102 days
Fluoresceine
Modification of the basal status evaluated with fluorescein test Approximately 2-3 minutes following fluorescein instillation, corneal staining was to be evaluated in both eyes, using a slit lamp, based on the Oxford scale (grades of 0-5: 0 is normal, 5 is severe abnormal).
Time frame: Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day), up to approximately 102 days
Endothelial Cell Counts
Modification of the basal status of the Endothelial cell counts evaluated with the specular microscopy
Time frame: Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day), up to approximately 102 days
Corneal Thickness
Modification of the basal status of the assesment (Corneal thickness). Measurement of the central corneal thickness was to be performed with a pachymeter
Time frame: Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day), up to approximately 102 days
Best Far Corrected Visual Acuity
Modification of the basal status of the assesment evaluated by LogMAR (Logarithm of the Minimum Angle of Resolution). When using a LogMAR chart, visual acuity is scored with reference to the logarithm of the minimum angle of resolution, as the chart's name suggests. An observer who can resolve details as small as 1 minute of visual angle scores LogMAR 0, since the base-10 logarithm of 1 is 0; an observer who can resolve details as small as 2 minutes of visual angle (i.e., reduced acuity) scores LogMAR 0.3, since the base-10 logarithm of 2 is near-approximately 0.3; and so on.
Time frame: Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day), up to approximately 102 days
Number of Participants With Abnormalities of the Retina, Macula, or Optic Nerve by Fundoscopy
Modification of the basal status of the assesment. Dilated fundus examination on retina, macula, optic nerve.
Time frame: Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day), up to approximately 102 days
Intra-ocular Pressure
Modification of the basal status of the assesment. Intraocular pressure (in mmHg) was assessed according to site current practice (air puff or applanation tonometer).
Time frame: Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day), up to approximately 102 days
Surgeon Satisfaction
Evaluation of surgeon satisfaction. Surgeon satisfaction was assessed through the question "How do you consider the study product global tolerance?", at a scale (a score of 0 is the minimum value with the best outcome and 3 is the maximum value with the worst outcome): (0) Very satisfactory, (1) Satisfactory, (2) Not very satisfactory, (3) Unsatisfactory. It is recorded at V2 and filled in by the surgeon who had performed the study. It is measured at Visit 2.
Time frame: day 1 - visit2 (Inclusion visit/Surgery)
Patient Global Satisfaction
Patient global satisfaction at D1 based on a 5-question questionnaire read by a masked observer. A question read by a masked observer assessed the patient satisfaction about the overall anesthesia during the surgery: "Overall, how satisfied are you with the topical study product used for your local anesthesia during your cataract surgery?" It was measured with 5 possible answers (Likert satisfaction scale): Very satisfied (0), Globally satisfied (1), Neither satisfied nor Unsatisfied (2), Globally unsatisfied (3), Very unsatisfied (4). It was measured at Visit 3.
Time frame: day 1 - visit2 (Inclusion visit/Surgery) after the treatment
In total, 410 subjects were screened in the study, 64 of which were dropped as screen failure and 346 were randomised to receive a treatment. From the 346 subjects randomised, 338 were treated and received the drug that was assigned at the randomization procedure, while 8 discontinued before treatment. Eventually, 335 subjects completed the study since discontinuation issues occurred for three subjects, one due to an AE and two lost to follow-up
| Milestone | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Started | 167 | 171 |
| Completed | 167 | 168 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
Τhe primary endpoint is the number of partecipants in each treatment group with a successful surface anesthesia, without any supplementation at the time point T4 (1 minute after the 3rd drop installation)
| participants | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Anesthesia Success | 153 | 152 |
| Anesthesia NO Success | 14 | 19 |
Changes in ocular symptoms (pain, irritation/burning/stinging, foreign body sensation) will be graded by the patients according to the following scale (0 is the minimum value and 3 is tha maximum value) (0 = absent, 1 = mild, 2 = moderate, 3 = severe) during the study on Visit 1-selection and on visit 4-final
| score on a scale | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Foreign Body Sensation visit1 | 0.08 ± 0.32 | 0.06 ± 0.33 |
| Foreign Body Sensation visit4 | 0.19 ± 0.43 | 0.17 ± 0.41 |
| Irritation/Burning/Stinging visit1 | 0.11 ± 0.33 | 0.11 ± 0.37 |
| Irritation/Burning/Stinging visit4 | 0.11 ± 0.36 | 0.15 ± 0.39 |
| pain visit1 | 0.01 ± 0.11 | 0.01 ± 0.08 |
| pain visit4 | 0.05 ± 0.24 | 0.05 ± 0.24 |
- Objective ocular signs assessed by slit lamp examination, flare, and other objective ocular signs will be graded according to the following scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The minimum value is 0 and maximum value is 3
| score on a scale | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Anterior Chamber Cells and Flare visit1 | 0 ± 0 | 0 ± 0 |
| Anterior Chamber Cells and Flare visit4 | 0.04 ± 0.24 | 0.03 ± 0.2 |
| Chemosis visit1 | 0.03 ± 0.17 | 0.04 ± 0.23 |
| Chemosis visit4 | 0.09 ± 0.33 | 0.09 ± 0.33 |
Modification of the basal status evaluated with fluorescein test Approximately 2-3 minutes following fluorescein instillation, corneal staining was to be evaluated in both eyes, using a slit lamp, based on the Oxford scale (grades of 0-5: 0 is normal, 5 is severe abnormal).
| score on a scale | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Corneal Fluorescein Staining visit1 | 0.21 ± 0.61 | 0.16 ± 0.52 |
| Corneal Fluorescein Staining visit4 | 0.32 ± 0.68 | 0.25 ± 0.66 |
Modification of the basal status of the Endothelial cell counts evaluated with the specular microscopy
| cell/mm^2 | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Endothelial Cells Count [cell/mm2] visit1 | 2440.76 ± 378 | 2511.89 ± 325.32 |
| Endothelial Cells Count [cell/mm2] visit4 | 2049.88 ± 620.43 | 2166.96 ± 517.41 |
Modification of the basal status of the assesment (Corneal thickness). Measurement of the central corneal thickness was to be performed with a pachymeter
| um | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| visit 1 (Day -90/Day -1) | 539.59 ± 39.3 | 536.59 ± 37.16 |
| visit 4 (Day 8 ± 1 day) | 557.8 ± 48.8 | 546.54 ± 42.15 |
Modification of the basal status of the assesment evaluated by LogMAR (Logarithm of the Minimum Angle of Resolution). When using a LogMAR chart, visual acuity is scored with reference to the logarithm of the minimum angle of resolution, as the chart's name suggests. An observer who can resolve details as small as 1 minute of visual angle scores LogMAR 0, since the base-10 logarithm of 1 is 0; an observer who can resolve details as small as 2 minutes of visual angle (i.e., reduced acuity) scores LogMAR 0.3, since the base-10 logarithm of 2 is near-approximately 0.3; and so on.
| LogMAR | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Best Corrected Visual Acuity LogMAR visit1 | 0.49 ± 0.31 | 0.47 ± 0.32 |
| Best Corrected Visual Acuity LogMAR visit4 | 0.12 ± 0.19 | 0.08 ± 0.15 |
Modification of the basal status of the assesment. Dilated fundus examination on retina, macula, optic nerve.
| Participants | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| macula abnormal V1 | 15 | 16 |
| macula abnormal V4 | 13 | 10 |
| optic nerve abnormal V1 | 16 | 16 |
| optic nerve abnormal V4 | 12 | 10 |
| retina abnormal V1 | 13 | 11 |
| retina abnormal V4 | 13 | 12 |
Modification of the basal status of the assesment. Intraocular pressure (in mmHg) was assessed according to site current practice (air puff or applanation tonometer).
| mmHg | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| visit 1 Selection | 15 ± 2.69 | 15 ± 2.46 |
| visit 4 Final | 14.7 ± 2.8 | 14.88 ± 3.05 |
Evaluation of surgeon satisfaction. Surgeon satisfaction was assessed through the question "How do you consider the study product global tolerance?", at a scale (a score of 0 is the minimum value with the best outcome and 3 is the maximum value with the worst outcome): (0) Very satisfactory, (1) Satisfactory, (2) Not very satisfactory, (3) Unsatisfactory. It is recorded at V2 and filled in by the surgeon who had performed the study. It is measured at Visit 2.
| score on a scale | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Surgeon Satisfaction | 0.17 ± 0.41 | 0.17 ± 0.47 |
Patient global satisfaction at D1 based on a 5-question questionnaire read by a masked observer. A question read by a masked observer assessed the patient satisfaction about the overall anesthesia during the surgery: "Overall, how satisfied are you with the topical study product used for your local anesthesia during your cataract surgery?" It was measured with 5 possible answers (Likert satisfaction scale): Very satisfied (0), Globally satisfied (1), Neither satisfied nor Unsatisfied (2), Globally unsatisfied (3), Very unsatisfied (4). It was measured at Visit 3.
| score on a scale | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| Patient Global Satisfaction | 1.35 ± 0.66 | 1.27 ± 0.52 |
Collected over Adverse events were to be monitored throughout the course of the study Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day)) up to "Visit 5 (Day 28 ± 3 days; approximately 129 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chloroprocaine 3% | 0/167 (0%) | 0/167 (0%) | 14/167 (8.4%) |
| Tetracaine 0.5% | 0/171 (0%) | 0/171 (0%) | 19/171 (11.1%) |
| Event | Chloroprocaine 3% | Tetracaine 0.5% |
|---|---|---|
| corneal edemaEye disorders | 5/167 | 2/171 |
| blood pressure increasedInvestigations | 0/167 | 3/171 |
| Intraocular pressure increasedInvestigations | 1/167 | 3/171 |
| general disorderEye disorders | 2/167 | 0/171 |
| Conjunctival hemorrhageEye disorders | 1/167 | 0/171 |
| hyperesthesiaEye disorders | 1/167 | 0/171 |
| photophobiaEye disorders | 1/167 | 1/171 |
| keratitisEye disorders | 1/167 | 1/171 |
| Retinal pigment epitheliopathyEye disorders | 1/167 | 0/171 |
| pyrexiaEye disorders | 1/167 | 0/171 |
| Age, Continuous(years) | Chloroprocaine 3% | Tetracaine 0.5% | Total |
|---|---|---|---|
| Mean | 70.3 ± 10.3 | 68.8 ± 9.9 | 69.9 ± 10.1 |
| Sex: Female, Male(Participants) | Chloroprocaine 3% | Tetracaine 0.5% | Total |
|---|---|---|---|
| Female | 94 | 86 | 180 |
| Male | 73 | 85 | 158 |
| Race and Ethnicity Not Collected(Participants) | Chloroprocaine 3% | Tetracaine 0.5% | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Mar 2021, 5 months.
Results were first posted in Oct 2022, 1 year 7 months after primary completion.
Of 23 industry-sponsored phase 3 interventional studies under Cataract, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's 5 months is below that.
Counting every sponsor, half of 31 studies reached it within 13 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chloroprocaine
Sintetica SA